Prothena Corporation PLC Company Profile (NASDAQ:PRTA)

About Prothena Corporation PLC (NASDAQ:PRTA)

Prothena Corporation PLC logoProthena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PRTA
  • CUSIP: N/A
  • Web: www.prothena.com
Capitalization:
  • Market Cap: $2.22 billion
  • Outstanding Shares: 38,275,000
Average Prices:
  • 50 Day Moving Avg: $62.65
  • 200 Day Moving Avg: $57.71
  • 52 Week Range: $40.58 - $70.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.02
  • P/E Growth: 0.78
Sales & Book Value:
  • Annual Revenue: $27.53 million
  • Price / Sales: 80.57
  • Book Value: $12.76 per share
  • Price / Book: 4.54
Profitability:
  • EBITDA: ($135,600,000.00)
  • Net Margins: -527.56%
  • Return on Equity: -33.20%
  • Return on Assets: -27.66%
Debt:
  • Current Ratio: 12.93%
  • Quick Ratio: 12.93%
Misc:
  • Average Volume: 227,002 shs.
  • Beta: 2.59
  • Short Ratio: 22.03
 

Frequently Asked Questions for Prothena Corporation PLC (NASDAQ:PRTA)

What is Prothena Corporation PLC's stock symbol?

Prothena Corporation PLC trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena Corporation PLC's earnings last quarter?

Prothena Corporation PLC (NASDAQ:PRTA) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.89) by $0.43. The company earned $26.81 million during the quarter, compared to analysts' expectations of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The business's quarterly revenue was up 7951.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.18) earnings per share. View Prothena Corporation PLC's Earnings History.

When will Prothena Corporation PLC make its next earnings announcement?

Prothena Corporation PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Prothena Corporation PLC.

Where is Prothena Corporation PLC's stock going? Where will Prothena Corporation PLC's stock price be in 2017?

12 brokerages have issued 12-month price objectives for Prothena Corporation PLC's shares. Their forecasts range from $69.00 to $100.00. On average, they expect Prothena Corporation PLC's stock price to reach $79.73 in the next twelve months. View Analyst Ratings for Prothena Corporation PLC.

What are analysts saying about Prothena Corporation PLC stock?

Here are some recent quotes from research analysts about Prothena Corporation PLC stock:

  • 1. Cantor Fitzgerald analysts commented, "Gotta be in it to win it. The logic behind impeding cell trafficking as a means treating T cell-mediated autoimmune disorders has been established with Tysabri in relapsing forms of MS, so the merits of pursuing non-CNS indications makes abundant sense to us." (9/28/2017)
  • 2. According to Zacks Investment Research, "The narrower-than-expected loss in the second quarter was encouraging. Prothena’s efforts on developing its pipeline are encouraging. The company's license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive. The collaboration not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. Prothena recently earned a $30 million of milestone payment from Roche. The company’s shares have outperformed the industry in the past one year. We expect investor focus to remain on further updates from its late-stage candidate, NEOD001. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates." (8/11/2017)
  • 3. Instinet analysts commented, "We are initiating on Prothena Corporation (PRTA) with a Buy rating and an $87 target price. We recommend owning PRTA shares ahead of Phase 2b PRONTO trial readout expected in early 2018 for lead asset NEOD001 in AL amyloidosis (a >$1.5bn peak sales opportunity). We view the pullback from 2016 highs and recent lows as an opportunity to accumulate the shares ahead of PRONTO data. Positive results from PRONTO based on change in NT-proBNP, a biomarker that NEOD001 substantially moved, yielding 53% responder rate in an early Phase 1/2b, are likely to support a conditional approval in the EU by 2019. In addition, we expect biomarker data from the PRX003 Phase 1b study to define mechanistically the breadth opportunity for MCAM/Th17-cell targeting in autoimmune disease, a potential multibillion dollar opportunity that, in our view, will raise the floor on PRTA's valuation. PRX002 could become a strong driver of PRTA's valuation in out years; however, given few near-term catalysts, it is unlikely to be a driver for PRTA shares in the next 12 months." (3/1/2017)

Who are some of Prothena Corporation PLC's key competitors?

Who are Prothena Corporation PLC's key executives?

Prothena Corporation PLC's management team includes the folowing people:

  • Lars G. Ekman M.D., Ph.D., Independent Chairman of the Board
  • Gene G. Kinney Ph.D., President, Chief Executive Officer, Director
  • Tran B. Nguyen, Chief Financial Officer
  • Karin L. Walker CPA, Chief Accounting Officer, Controller
  • Wagner Zago, Chief Scientific Officer
  • Arthur W. Homan, Chief Legal Officer
  • Carol D. Karp, Chief Regulatory Officer
  • Martin Koller M.D., Chief Medical Officer
  • Tara Nickerson Ph.D., Chief Business Officer
  • K. Anders O. Harfstrand M.D., Ph.D., Director

Who owns Prothena Corporation PLC stock?

Prothena Corporation PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include Nationwide Fund Advisors (0.05%) and Strs Ohio (0.01%). Company insiders that own Prothena Corporation PLC stock include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Lars Ekman, Martin Koller, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena Corporation PLC.

Who sold Prothena Corporation PLC stock? Who is selling Prothena Corporation PLC stock?

Prothena Corporation PLC's stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors. Company insiders that have sold Prothena Corporation PLC stock in the last year include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker and Tara Nickerson. View Insider Buying and Selling for Prothena Corporation PLC.

Who bought Prothena Corporation PLC stock? Who is buying Prothena Corporation PLC stock?

Prothena Corporation PLC's stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio. View Insider Buying and Selling for Prothena Corporation PLC.

How do I buy Prothena Corporation PLC stock?

Shares of Prothena Corporation PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena Corporation PLC's stock price today?

One share of Prothena Corporation PLC stock can currently be purchased for approximately $57.95.


MarketBeat Community Rating for Prothena Corporation PLC (NASDAQ PRTA)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  422
MarketBeat's community ratings are surveys of what our community members think about Prothena Corporation PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Prothena Corporation PLC (NASDAQ:PRTA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 12 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $79.73 (37.58% upside)
Consensus Price Target History for Prothena Corporation PLC (NASDAQ:PRTA)
Price Target History for Prothena Corporation PLC (NASDAQ:PRTA)
Analysts' Ratings History for Prothena Corporation PLC (NASDAQ:PRTA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017Deutsche Bank AGSet Price TargetBuy$73.00N/AView Rating Details
10/2/2017Jefferies Group LLCReiterated RatingBuy$100.00LowView Rating Details
10/2/2017SunTrust Banks, Inc.Reiterated RatingBuy$75.00LowView Rating Details
9/29/2017Royal Bank Of CanadaReiterated RatingBuyHighView Rating Details
9/29/2017BTIG ResearchLower Price TargetBuy -> Buy$80.00 -> $77.00HighView Rating Details
9/28/2017Cantor FitzgeraldReiterated RatingBuy$79.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$83.00HighView Rating Details
7/6/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$70.00LowView Rating Details
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMediumView Rating Details
4/3/2017WedbushReiterated RatingOutperform$77.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$87.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/AView Rating Details
8/4/2016Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Prothena Corporation PLC (NASDAQ:PRTA)
Earnings by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Earnings History by Quarter for Prothena Corporation PLC (NASDAQ PRTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($1.41)N/AView Earnings Details
8/8/20176/30/2017($0.89)($0.46)$16.08 million$26.81 millionViewN/AView Earnings Details
5/9/20173/31/2017($1.32)($0.99)$0.26 million$0.26 millionViewN/AView Earnings Details
2/14/2017Q416($1.12)($1.41)$5.35 million$0.20 millionViewListenView Earnings Details
11/1/2016Q3($1.22)($1.26)$0.49 million$0.29 millionViewN/AView Earnings Details
8/2/2016Q2($0.91)($1.18)$0.39 million$0.33 millionViewN/AView Earnings Details
5/3/2016Q116($0.77)($0.81)$0.27 million$0.27 millionViewN/AView Earnings Details
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details
11/2/2015($0.66)($0.73)$0.28 million$0.43 millionViewN/AView Earnings Details
8/4/2015Q2($0.56)($0.59)$0.60 million$0.28 millionViewN/AView Earnings Details
5/5/2015($0.59)($0.55)$1.95 million$0.59 millionViewN/AView Earnings Details
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details
8/4/2014Q214$0.06$15.17 million$15.12 millionViewN/AView Earnings Details
5/5/2014$0.81$0.78$30.17 million$32.23 millionViewN/AView Earnings Details
3/6/2014Q113($0.52)ViewN/AView Earnings Details
3/28/2013Q412($0.82)$0.13 million$0.58 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Prothena Corporation PLC (NASDAQ:PRTA)
2017 EPS Consensus Estimate: ($5.08)
2018 EPS Consensus Estimate: ($4.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.42)($1.28)($1.36)
Q2 20174($1.20)($0.50)($0.87)
Q3 20174($1.54)($1.21)($1.36)
Q4 20174($1.77)($1.27)($1.49)
Q1 20181($1.27)($1.27)($1.27)
Q2 20181($1.24)($1.24)($1.24)
Q3 20181($1.08)($1.08)($1.08)
Q4 20181($0.99)($0.99)($0.99)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Prothena Corporation PLC (NASDAQ:PRTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Prothena Corporation PLC (NASDAQ:PRTA)
Insider Ownership Percentage: 3.10%
Insider Trades by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Insider Trades by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Dennis J SelkoeDirectorSell3,500$64.17$224,595.00View SEC Filing  
9/28/2017Christopher S HenneyDirectorSell900$70.00$63,000.00View SEC Filing  
9/28/2017Gene G KinneyInsiderSell2,800$70.00$196,000.00View SEC Filing  
9/27/2017Tara NickersonInsiderSell4,724$69.05$326,192.20View SEC Filing  
9/25/2017Tara NickersonInsiderSell17,500$63.60$1,113,000.00View SEC Filing  
7/17/2017Karin L WalkerInsiderSell5,000$64.89$324,450.00View SEC Filing  
7/7/2017Dennis J SelkoeDirectorSell3,500$58.11$203,385.00View SEC Filing  
4/17/2017Karin L WalkerInsiderSell5,000$52.25$261,250.00View SEC Filing  
4/3/2017Dennis J SelkoeDirectorSell3,500$55.86$195,510.00View SEC Filing  
3/9/2017Tran NguyenCFOBuy1,000$51.32$51,320.00View SEC Filing  
1/4/2017Arthur W HomanInsiderSell3,125$52.25$163,281.25View SEC Filing  
11/28/2016Dennis J SelkoeDirectorSell5,000$62.42$312,100.00View SEC Filing  
11/9/2016Gene G KinneyInsiderSell8,548$55.32$472,875.36View SEC Filing  
10/21/2016Gene G KinneyInsiderSell20,619$55.10$1,136,106.90View SEC Filing  
10/13/2016Karin L WalkerInsiderSell5,000$54.23$271,150.00View SEC Filing  
9/19/2016Karin L WalkerInsiderSell12,000$61.10$733,200.00View SEC Filing  
9/1/2016Arthur W HomanInsiderSell3,125$52.16$163,000.00View SEC Filing  
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.50View SEC Filing  
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.00View SEC Filing  
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.00View SEC Filing  
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.00View SEC Filing  
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.50View SEC Filing  
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00View SEC Filing  
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.00View SEC Filing  
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.25View SEC Filing  
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.00View SEC Filing  
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.00View SEC Filing  
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.00View SEC Filing  
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.00View SEC Filing  
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.00View SEC Filing  
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Prothena Corporation PLC (NASDAQ:PRTA)
Latest Headlines for Prothena Corporation PLC (NASDAQ:PRTA)
Source:
Loading headlines, please wait.

Social

Chart

Prothena Corporation PLC (PRTA) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.